Tie2-binding agents and methods of use
AssigneeGenentech, Inc.
InventorsMinhong YAN, Gu ZHANG, Nicholas John AGARD, Danielle Marie DICARA, Philip E. HASS, Julie Q. HANG, Erin L. CHRISTENSEN, Robert Paul MORSE, Sarah SANOWAR, Vittal SHIVVA
Life of this patent
Estimating the term…
Abstract
The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
Claims48
An isolated antibody or antigen-binding fragment thereof that specifically binds to Tie2, wherein the antibody or fragment thereof comprises:
- a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence NTDIS (SEQ ID NO:3), (b) CDR-H2 comprising the amino acid sequence RISPSDGNTYYADSVKG (SEQ ID NO:4), and (c) CDR-H3 comprising the amino acid sequence RTRWASX1AX2DY (SEQ ID NO:5), where X1 is M, L, K, F, Y, R, N, Q, H or W and/or or X2 is F, Y L, Q, I, K, or H, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO:8), (e) CDR-L2 comprising the amino acid sequence SASFLYS (SEQ ID NO:9), and (f) CDR-L3 comprising the amino acid sequence QQSYTTPPT (SEQ ID NO:10).
The antibody or antigen-binding fragment thereof of any one of the preceding claims, which is a monoclonal antibody, a humanized antibody, an antibody fragment, and/or a chimeric antibody.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, which is a Fab fragment that binds Tie2.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody comprises the VL sequence of SEQ ID NO:21 and a VH sequence of SEQ ID NO:20.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, comprising a LC comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:25 and a HC comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:55.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, comprising a LC comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:25 and a HC comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:55.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody comprises a LC comprising the sequence of SEQ ID NO:25 and a HC comprising the sequence of SEQ ID NO:55.
The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the HC constant regions terminates at position 221 (EU numbering).
An antibody or antigen-binding fragment thereof that specifically binds to Tie-2 wherein the antibody comprises a HC sequence of SEQ ID NO:55 and a LC sequence of SEQ ID NO:25.
An antibody or antigen-binding fragment thereof that specifically binds to Tie-2 wherein the antibody comprises a HC sequence of SEQ ID NO:23 and a LC sequence of SEQ ID NO:56.
An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof of any of the preceding claims.
A conjugate which binds Tie2 comprising:
- a Fab comprising a HC having SEQ ID NO:55 and a LC having SEQ ID NO:25;
- conjugated to a polyol which has the structure of Formula 1(b)
- where each m is independently an integer from 20-30, where R1 and R2 taken together has the structure
- where R2 is a maleamide;
- and
- wherein the polyol is linked to the Fab HC at residue C209 (EU numbering).
Dependencies are inferred from the claim text.